Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 2Esophageal Neoplasms 2Squamous-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Gefitinib 9Pemetrexed 7Carboplatin 5Gemcitabine 4Cisplatin 4apatinib 3Docetaxel 3aflutinib 2Neoadjuvant Therapy 2Erlotinib Hydrochloride 2Bevacizumab 2tislelizumab 1pembrolizumab 1motesanib diphosphate 1lometrexol 1icotinib 1endostar protein 1camrelizumab 1Watchful Waiting 1Thymalfasin 1Radiomics 1Platinum Compounds 1Paclitaxel 1Lymph Node Excision 1Indium 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Folic Acid 1Exome 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma of Lung × Platinum Compounds × Clear all
NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Cancer Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡